Related Experiment Video
Updated: May 27, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Sunitinib for advanced pancreatic neuroendocrine tumors
Richard A Hubner1, Juan W Valle
1Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK.
Abstract:
Recent recognition of the high prevalence of neuroendocrine tumors in combination with a sustained failure to improve outcomes for patients with advanced disease has elevated their priority for research and drug development. Sunitinib (SU11248, Sutent; Pfizer Inc. NY, USA) potently inhibits multiple-receptor tyrosine kinases, resulting in antiangiogenic effects. A growing body of evidence indicates angiogenesis is a clinically relevant therapeutic target in pancreatic neuroendocrine tumors, culminating in a Phase III randomized study of sunitinib in patients with advanced progressive pancreatic neuroendocrine tumors. Sunitinib has recently gained regulatory approval as a single agent in this setting, and future studies will investigate most appropriate patient selection, and sequencing and combination with other targeted and cytotoxic agents. Here, we discuss in detail the molecular properties, clinical efficacy and safety of sunitinib in the context of pancreatic neuroendocrine tumors.
Insights
Sunitinib, an antiangiogenic drug, shows promise for advanced pancreatic neuroendocrine tumors. Further research will explore optimal use in combination therapies for improved patient outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Neuroendocrine tumors (NETs) are prevalent, with limited treatment options for advanced stages.
- Angiogenesis is a critical factor in pancreatic neuroendocrine tumor (PNET) progression.
Purpose of the Study:
- To review the molecular properties, clinical efficacy, and safety of sunitinib for advanced PNETs.
- To discuss sunitinib's role as a targeted therapy in PNET treatment.
Main Methods:
- Review of preclinical data and clinical trial results for sunitinib in PNETs.
- Analysis of sunitinib's mechanism of action, targeting multiple receptor tyrosine kinases.
Main Results:
- Sunitinib demonstrates potent inhibition of receptor tyrosine kinases, leading to antiangiogenic effects.
- Phase III studies support sunitinib's efficacy in advanced progressive PNETs.
Conclusions:
- Sunitinib is approved as a single agent for advanced PNETs.
- Future research will focus on patient selection, combination therapies, and optimal sequencing of sunitinib.
